850 PATIENTS WITH MAFLD TAKING GLUCAGON LIKE PEPTIDE-1 RECEPTOR AGONISTS DO NOT HAVE HIGHER INCIDENCE FOR HEPATOBILIARY CANCER BUT HAVE LOWER OVERALL MORTALITY: A MULTI-CENTER ANALYSIS. | Publicación